title: The Risk for Cardiovascular Events Associated with Hyperlipdemia among Patients with and Without Rheumatoid Arthritis.
abstract: OBJECTIVE
  To determine, using data from a real-world setting, the overall and sex-specific risk of cardiovascular (CV) events in patients with rheumatoid arthritis (RA), with or without comorbid hyperlipidemia, relative to those in a non-RA cohort.
  
  
  METHODS
  This retrospective cohort study using claims data from a US commercial health plan (2005-2011) included patients with RA and a matched non-RA cohort. Cox proportional hazards regression model determined the hazard ratio (HR) for CV events (myocardial infarction, stroke, revascularization procedures), using the presence of RA and hyperlipidemia as the independent variables, controlling for other covariates (age, sex, diabetes, and hypertension).
  
  
  RESULTS
  The incidence of CV events per 1000 person-years was 10.19 for the RA cohort and 6.41 for the non-RA cohort (crude rate ratio [RR] =1.59). Within the RA cohort, incidence was 15.54 for patients with hyperlipidemia and 7.05 for patients without hyperlipidemia (crude RR=2.21); in the non-RA cohort, incidence was 10.55 and 3.82 for those with and without hyperlipidemia, respectively (crude RR=2.76). After controlling for covariates, the HR of CV events among RA patients was 1.68 (95% CI: 1.50, 1.87) relative to non-RA patients. After multivariable adjustment, hyperlipidemia conferred a significant risk of CV events in both RA and non-RA patients; the interaction between RA and hyperlipidemia was not significant (p=0.13).
  
  
  CONCLUSIONS
  This real-world analysis demonstrates that patients with RA have an increased risk of CV events. Similar to a non-RA cohort, CV event rates were incrementally higher for those patients with hyperlipidemia.
  
  
  CONCLUSIONS
  Cardiovascular disease is an increasingly visible topic of concern in the rheumatoid arthritis community. However, there are only limited data that informs both the absolute and relative rates of CVD events, and the contribution of various risk factors such as hyperlipidemia, compared to non-RA populationsThe 'lipid paradox' hypothesis in RA suggests that elevated LDL cholesterol has a negligible effect on CVD risk in RA, unlikely in the general population where it is a well-accepted CVD risk factorThe incidence of CVD events in RA patients was 10/1000 patient years, a 1.6 fold greater risk compared to non-RA patientsThe contribution of hyperlipidemia to CVD risk was associated with comparable or greater absolute increases in the rate of CV events compared to non RA patients, a finding that does not support the lipid paradox.
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Anagha
authors.initials: A
authors.lastname: Nadkarni
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Min
authors.initials: M
authors.lastname: You
authors.affiliation: University of Alabama at Birmingham, AL, USA.
authors.forename: Holly
authors.initials: H
authors.lastname: Resuehr
authors.affiliation: University of Alabama at Birmingham, AL, USA.
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Curtis
keywords: Cardiovascular disease; Hyperlipidemia; Inflammation; Rheumatoid arthritis
references.citation: Ann Rheum Dis. 2010 Feb;69(2):325-31
references.pmid: 19773290
references.citation: Clin Rheumatol. 2010 Sep;29(9):947-55
references.pmid: 20383550
references.citation: Clin Exp Rheumatol. 2009 May-Jun;27(3):446-51
references.pmid: 19604437
references.citation: Ann Rheum Dis. 2006 Dec;65(12):1608-12
references.pmid: 16793844
references.citation: Arthritis Rheum. 2003 Jul;48(7):1833-40
references.pmid: 12847676
references.citation: J Rheumatol. 2006 Nov;33(11):2167-72
references.pmid: 16981296
references.citation: Arthritis Rheum. 2005 Aug;52(8):2293-9
references.pmid: 16052597
references.citation: Circulation. 2003 Mar 11;107(9):1303-7
references.pmid: 12628952
references.citation: Ann Rheum Dis. 2008 Jan;67(1):64-9
references.pmid: 17517756
references.citation: Rheumatology (Oxford). 2008 Oct;47(10 ):1543-7
references.pmid: 18687711
references.citation: Arthritis Rheum. 2005 Feb;52(2):402-11
references.pmid: 15693010
references.citation: JAMA. 2000 Jul 19;284(3):311-8
references.pmid: 10891962
references.citation: Arthritis Rheum. 2008 Dec 15;59(12):1690-7
references.pmid: 19035419
references.citation: Ann Rheum Dis. 2012 Jun;71(6):862-8
references.pmid: 22267329
references.citation: Ann Rheum Dis. 2007 Nov;66(11):1503-7
references.pmid: 17472994
references.citation: Ann Rheum Dis. 2011 Mar;70(3):482-7
references.pmid: 21216812
references.citation: Ann Rheum Dis. 2010 Jul;69(7):1310-4
references.pmid: 19854708
references.citation: Vaccine. 2013 Dec 30;31 Suppl 10:K41-61
references.pmid: 24331074
references.citation: Semin Arthritis Rheum. 2009 Apr;38(5):372-81
references.pmid: 18395771